Navigation Links
Hepatitis C Therapy Useless for Some

Those who don't respond at first not helped by maintenance treatment, study shows

WEDNESDAY, Dec. 3 (HealthDay News) -- Maintenance therapy using low-dose peginterferon doesn't help patients with advanced chronic hepatitis C who haven't responded to an initial round of treatment, new research suggests.

The study also showed a surprising health decline in patients with liver disease over the course of four years.

"This course of treatment had been adopted by a number of doctors in the U.S. and in other countries, though it had yet to be proven to work. That practice should be stopped, based on the results of this trial. There is no rationale for using maintenance therapy. The treatment is clearly ineffective," study author Dr. Adrian Di Bisceglie, chief of hepatology and co-director of the Liver Center at Saint Louis University, said in a university news release.

About half of patients with chronic hepatitis C fully recover after an initial course of peginterferon and ribavirin antiviral therapy that can last from six months to a year. Other patients (non-responders) may show improvement, but the virus isn't eliminated.

The study included 1,050 non-responder patients with advanced liver disease. Half of them received low doses of peginterferon for 3.5 years to try to suppress the hepatitis C virus and slow progression of liver disease. The other patients were assigned to a control group.

After four years, 30 percent of patients in both groups had developed liver failure, liver cancer, or had died. Among those who had milder cirrhosis at the start of the study, 10 percent to 12 percent developed severe liver disease. Both of these findings surprised the researchers.

"Hepatitis patients in these circumstances got very ill over the course of four years, surprisingly so. The lesson we learned is that once chronic hepatitis C gets to the stage of advanced fibrosis, patients can decline rapidly," De Bisceglie said.

The study was published in the Dec. 4 issue of the New England Journal of Medicine.

About 4 million people in the United States are infected with hepatitis C, and 10,000 to 12,000 of them die each year. Hepatitis C is caused by virus that's transmitted through direct contact with an infected person's blood.

More information

The U.S. Centers for Disease Control and Prevention has more about hepatitis C.

-- Robert Preidt

SOURCE: Saint Louis University, news release, Dec. 3, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
2. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
3. Stanford researchers find way to fight treacherous hepatitis B
4. Medical Services International Agrees to Retail the VScan Hepatitis B&C Test Kits in SE Asia
5. Hepatitis A Vaccine Best Bet to Treat Virus
6. Hepatitis C Testing Recommended for Anyone with a Tattoo
7. Is it pancreatitis in acute abdominal pain in acute viral hepatitis?
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
10. Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
11. HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
Post Your Comments:
Related Image:
Hepatitis C Therapy Useless for Some 
(Date:11/27/2015)... , ... November 27, 2015 , ... CBD College ... of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. ... accredited colleges, as only one of twelve colleges and universities in the state of ...
(Date:11/27/2015)... ... , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his search ... one of Joplin's most famous and beautiful concert posters. The concert was held on ... Arbor. The According to Hawley, "It is hard to believe that Joplin's stardom was ...
(Date:11/26/2015)... Las Vegas, NV (PRWEB) , ... November 26, 2015 , ... ... holiday shopping strategy. Many customers choose to buy during the Black Friday and ... holiday gifts. Shoppers don’t need to search the Internet high and low to find ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... ... 26, 2015 , ... WorldCare International, Inc., the first company ... Employee Benefits Conference. The Employee Benefits Conference was hosted by the International Foundation ... 11th, 2015. The conference was held at the Hawaii Convention Center in Honolulu, ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 27, 2015 --> ... go online. The potential to save costs, improve treatment ... far from fully exploited as yet. Here, particular emphasis ... either via mobile tablet or directly at the patients, ... ) -->      (Photo: ...
(Date:11/27/2015)... , Nov. 26, 2015 ... addition of the "2016 Global Tumor ... Country Volume and Sales Segment Forecasts, Innovative ... report to their offering. --> ... of the "2016 Global Tumor Marker ...
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
Breaking Medicine Technology: